 |
|
 |
- May 17, 2008 |
|
|
Welcome to the #1 online source of information for Diabetes Specialists! An international online community of more than 10,000 Diabetes Specialists.
CME on Diabetes is a website built to transmit top-level CME conferences given by international experts in endocrinology, insulin resistance, prediabetes, metabolic syndrome and type 2 diabetes. More than 2.6 million slides have been viewed since the website launch. Thank you for your continued support and commitment!
|
|
|
| Presentation |
|
"Markers of endothelial dysfunction and insulin resistance. Beneficial effects of rosiglitazone in type 2 diabetes"Prof. Paul Valensi (biography)
English - 2004-09-08 - 22 minutes
|
 | (21 slides) |
Summary :
In this presentation Prof. Valensi discusses the association between endothelial dysfunction and insulin resistance in patients with type 2 diabetes, and presents new data on the effects of rosiglitazone treatment on markers of endothelial dysfunction.
Type 2 diabetes (1) and insulin resistance (2) are associated with endothelial dysfunction, which is in turn an early step in the pathogenesis of atherosclerosis (1). The metabolic abnormalities in type 2 diabetes can induce molecular mechanisms having potentially deleterious effects on the structure and function of blood vessels (3).
Rosiglitazone which is a powerful PPAR gamma agonist, is known to impact various factors affecting cardiovascular disease (4,5). Prof. Valensi reviews data presented at the 2004 EASD meeting from a 12-week study of 136 type 2 diabetic patients randomized to rosiglitazone once daily or placebo once daily. Baseline associations of markers of endothelial dysfunction with parameters of insulin resistance were observed, as well as significant improvements after treatment in the levels of sE-selectin, PAI-1 antigen, tPA antigen and von Willebrand antigen.
Copyright © 2005 E-MedHosting.com Inc.
Learning objectives :
After viewing this presentation the participant will be able to discuss:
- The associations between type 2 diabetes and insulin resistance, and endothelial dysfunction
- Data from the 2004 EASD meeting supporting the beneficial impact of rosiglitazone on endothelial function in type 2 diabetes
Bibliographic references :
1. Russell Ross, Ph.D. Atherosclerosis — An Inflammatory DiseaseNEJM 1999;340:115.
2. AE Caballero, S Arora, R Saouaf, SC Lim, P Smakowski, JY Park, GL King, FW LoGerfo, ES Horton and A Veves Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetesDiabetes. 1999;48(9):1856.
3. Mark A. Creager, MD; Thomas F. Lüscher, MD, FRCP; and prepared with the assistance of Francesco Cosentino, MD, PhD; Joshua A. Beckman, MD Diabetes and Vascular Disease: Pathophysiology, Clinical Consequences, and Medical Therapy: Part ICirculation. 2003;108:1527.
4. Andreas Festa, MD; Ralph D’Agostino, Jr, PhD; George Howard, DrPH; Leena Mykkänen, MD, PhD; Russell P. Tracy, PhD; Steven M. Haffner, MD Chronic Subclinical Inflammation as Part of the Insulin Resistance Syndrome: The Insulin Resistance Atherosclerosis Study (IRAS) Circulation. 2000;102:42.
5. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition Annu Rev Med. 1993;44:121-31.
|
|
|
|
|
|
| Search our website |
 |
| |
Would you like to know more about insulin resistance? Are you looking for information pertaining to Type 2 Diabetes? You can find what you are looking for in over 2000 references available on CMEonDiabetes. |
| |
|
|
| Social |
|
| |
Let others know about this presentation.
|
|
|
|
